American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4005)
  2. Hematologic Malignancies, Division of (3808)
  3. Center for Hematologic Malignancies (3684)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1345)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (989)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (942)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1263)
  3. Research Letter (47)
  4. Review (43)
  5. Editorial (36)
  6. Guidelines (14)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4005)
  2. Hematologic Malignancies, Division of (3808)
  3. Center for Hematologic Malignancies (3684)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1345)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (349)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (72)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5175)
  2. Blood Advances (338)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5563)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The role of the adenosinergic pathway in the resistance to hypomethylating agents
    Meeting Abstract

    Vrachiolias, G.; Lamprianidou, E.; Tasis, A.; Spyropoulos, T.; Kymparidou, C.; Dimitriou, D.; Rimpa, C. M.; Misidou, C.; Liapis, K.; Papoutselis, M. K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • First results of asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors for patients with chronic myeloid leukemia who do not achieve a deep molecular remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)
    Meeting Abstract

    Cortes, J. E.; Mauro, M. J.; Visotcky, A.; Tantravahi, S. K.; Thompson, J. E.; Yang, J.; Baim, A.; Gao, Y.; Maldonado-Schmidt, S.; Olig, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Zeidan, A. M.; Stein, E. M.; Mauro, M. J.; Podoltsev, N. A.; Rampal, R.
    Blood (2024)

    Fulltext@MSK | Save
  • The role of adenosine deaminase acting on RNA 1 (ADAR1) enzyme in the resistance to hypomethylating agents
    Meeting Abstract

    Dimitriou, D.; Lamprianidou, E.; Kymparidou, C.; Spyropoulos, T.; Tasis, A.; Rimpa, C. M.; Vrachiolias, G.; Misidou, C.; Liapis, K.; Papoutselis, M. K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Cardinal: A phase I, multicenter, open-label, dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in chronic myeloid leukemia
    Meeting Abstract

    Jabbour, E.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Hughes, T. P.; Kim, D. W.; Kantarjian, H. M.; Holes, L.; Kuriakose, E. T.; Mauro, M. J.
    Blood (2024)

    Fulltext@MSK | Save
  • Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CDI9 specific CAR T-cell therapy
    Meeting Abstract

    Kunz, W. G.; Blumenberg, V.; Rejeski, K.; Sheik, G.; Brendel, M.; Von Bergwelt, M.; Subklewe, M.; Winkelmann, M.
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy and safety outcomes of CAR T-cell therapies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma who received prior treatment with mosunetuzumab
    Meeting Abstract

    Braun, A.; Schuster, S. J.; Nastoupil, L.; Bartlett, N. L.; Shadman, M.; Kumar, A.; Tzachanis, D.; Chihara, D.; Wu, M.; Wei, M. C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparison of progression-free survival of relapsed or refractory follicular lymphoma patients in a single-arm trial of tazemetostat with a real-world external control arm
    Meeting Abstract

    Salles, G.; Leonard, J. P.; Morschhauser, F.; Crowley, A.; Sosinsky, A. Z.; Lieb, C.; Zeldow, B.; Harton, J.; Wang, S.; Boyer, J.; more...
    Blood (2024)

    Fulltext@MSK | Save